We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+0.75%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.44B
AUM Growth
-$102M
(-4%)
Cap. Flow
-$54M
Cap. Flow
% of AUM
-2.21%
Top 10 Holdings %
Top 10 Hldgs %
38.65%
Holding
187
New
10
Increased
35
Reduced
38
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$45.2M |
| 2 |
Humana
HUM
|
+$23.9M |
| 3 |
Eli Lilly
LLY
|
+$20.3M |
| 4 |
Illumina
ILMN
|
+$20.1M |
| 5 |
Abbott
ABT
|
+$17.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$44.1M |
| 2 |
UnitedHealth
UNH
|
+$23.9M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$23.1M |
| 4 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$21.7M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$21.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.9% |
| 2 | Real Estate | 1.86% |
| 3 | Industrials | 0.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ITOS
176
DELISTED
iTeos Therapeutics
ITOS
| – | – |
-21,181
| Closed | -$436K |
|
177
Protagonist Therapeutics
PTGX
$8.62B
| – | – |
-122,271
| Closed | -$967K |
|
178
Qiagen
QGEN
$8.57B
| – | – |
-9,902
| Closed | -$496K |
|
179
Syndax Pharmaceuticals
SNDX
$1.72B
| – | – |
-56,480
| Closed | -$1.09M |
|
180
Universal Health Services
UHS
$9.94B
| – | – |
-4,000
| Closed | -$403K |
|
|
VRNA
181
DELISTED
Verona Pharma
VRNA
| – | – |
-751,905
| Closed | -$3.15M |
|
182
Waters Corp
WAT
$38.1B
| – | – |
-3,600
| Closed | -$1.19M |
|
|
ZIMV
183
DELISTED
ZimVie
ZIMV
| – | – |
-14,202
| Closed | -$227K |
|
|
SYNH
184
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| – | – |
-302,945
| Closed | -$21.7M |
|
|
HR
185
DELISTED
Healthcare Realty Trust Incorporated
HR
| – | – |
-104,024
| Closed | -$2.83M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, Tekla Capital Management held 187 positions worth $2.44B, down 4% from $2.54B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Tekla Capital Management's Q3 2022 filing shows 10 new, 35 increased, 38 reduced and 19 closed positions. Its largest new stake was Veradigm Inc. Common Stock: 428,580 shares worth $6.53M. The largest sale was McKesson, an estimated $44.1M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Real Estate and Industrials.
- Tekla Capital Management's largest Q3 2022 buy was Veradigm Inc. Common Stock: 428,580 shares worth $6.53M.
- Tekla Capital Management added most to Johnson & Johnson in Q3 2022, an estimated $45.2M increase.
- Tekla Capital Management's biggest Q3 2022 reduction was McKesson, cutting an estimated $44.1M.
- Tekla Capital Management fully exited Syneos Health, Inc. Class A Common Stock in Q3 2022, selling an estimated $21.7M.
- Tekla Capital Management's ten largest holdings make up 39% of its $2.44B portfolio in Q3 2022.
- Tekla Capital Management opened 10 new positions and closed 19 in Q3 2022.
- Tekla Capital Management's portfolio value fell 4% quarter-over-quarter to $2.44B.
Based on Tekla Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.